Equillium (EQ) Other Accumulated Expenses (2017 - 2026)
Equillium (EQ) posted quarterly Other Accumulated Expenses of $418000.0 for Q1 2026, down 35.59% year-over-year from $649000.0 in Q1 2025, and up 96.24% quarter-over-quarter from $213000.0 in Q4 2025.
Analysis
Equillium (EQ) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Other Accumulated Expenses for 10 consecutive years, with $418000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 35.59% year-over-year to $418000.0; the TTM figure through Mar 2026 stood at $418000.0 (down 35.59% YoY), while the FY2025 annual figure was $213000.0, down 29.7% from the prior year.
- Other Accumulated Expenses rose to $418000.0 in Q1 2026 per EQ's latest filing, from $213000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $749000.0 in Q3 2022 and bottomed at $129000.0 in Q2 2025.
- Historically, Other Accumulated Expenses has averaged $440647.1 across 5 years, with a median of $431000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 345.83% — and 2025, when it plunged 67.75%.
- Equillium's Other Accumulated Expenses stood at $472000.0 in 2022, then retreated by 8.69% to $431000.0 in 2023, then dropped by 29.7% to $303000.0 in 2024, then fell by 29.7% to $213000.0 in 2025, then jumped by 96.24% to $418000.0 in 2026.
- Business Quant data shows EQ's Other Accumulated Expenses at $418000.0 in Q1 2026, $213000.0 in Q4 2025, and $253000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 162,000.00 |
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 213,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 649,000.00 |
| Dec 31, 2024 | 303,000.00 |
| Sep 30, 2024 | 443,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 483,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 595,000.00 |
| Jun 30, 2023 | 661,000.00 |
| Mar 31, 2023 | 732,000.00 |
| Dec 31, 2022 | 472,000.00 |
| Sep 30, 2022 | 749,000.00 |
| Jun 30, 2022 | 252,000.00 |
| Mar 31, 2022 | 308,000.00 |
| Dec 31, 2021 | 245,000.00 |
| Sep 30, 2021 | 168,000.00 |